Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Cited by (548)

Items 401–500 of 548

1. B‐cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer
   Jiajian Wang, Sidi Li, Shudai Lin, Shuying Fu, Li Qiu, Ke Ding, Keying Liang, Hongli Du · 2020 · Cell Proliferation
2. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma
   Chuanxu Liu, Xinyu Ding, Gaoyang Li, Youping Zhang, Yubao Shao, Linyi Liu, Wenhao Zhang, Yujie Ma, Wenbin Guan, Lifeng Wang et al. · 2023 · iScience
3. Discovery of XZ338, a highly potent BCL-XL degrader
   Xuan Zhang, Dinesh Thummuri, Wanyi Hu, Xingui Liu, Peiyi Zhang, Shuo Zhou, Daohong Zhou, Guangrong Zheng · 2025 · European Journal of Medicinal Chemistry
4. Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting
   Zhe Wang, Mutian Tang, Marina Konopleva · 2026 · Oncogenesis
5. Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer
   Fernando Martín, Clara Alcon, Elba Marín, Paula Morales-Sánchez, Albert Manzano-Muñoz, Sherley Díaz, M. Lluïsa Pérez García, Josep Samitier, Albert Lu, Alberto Villanueva et al. · 2025 · Cell Death and Disease
6. Red Blood Cell BCL-xL Is Required for Plasmodium falciparum Survival: Insights into Host-Directed Malaria Therapies
   Coralie Boulet, Ghizal Siddiqui, Taylah L. Gaynor, Christian Doerig, Darren J. Creek, Teresa Gil Carvalho · 2022 · Microorganisms
7. Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis
   Lyndsey N. Moore, Daniel L. Holmes, Anjali Sharma, Joselyn Landazuri Vinueza, Michael Lagunoff · 2023 · PLoS Pathogens
8. Methods to Probe Conformational Activation and Mitochondrial Activity of Proapoptotic BAK
   Geetika Singh, Tudor Moldoveanu · 2018 · Methods in molecular biology
9. Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma
   Katja Korelin, Mayke Oostveen, Wafa Wahbi, Filipp Ianevski, Bruno Cavalcante, Laura Turunen, Ilya N Belevich, Ahmed Al‐Samadi, Tuula Anneli Salo · 2024 · Biomedicine & Pharmacotherapy
10. Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis
    Natalie L. Payne, Swee Heng Milon Pang, Andrew J. Freeman, Dilara Ceyda Ozkocak, Justin W Limar, Georgia Wallis, Di Zheng, Senora Mendonca, Lorraine Ann O’Reilly, Daniel H.D. Gray et al. · 2025 · Cell Death Discovery
11. Allosteric regulation of BH3-in-groove interactions by tail anchors of BCL-xL complexes limits BH3 mimetic antagonism
    Laurent Maillet, Aurélie Fétiveau, Lisenn Lalier-Bretaudeau, Nena Martin, Sophie Barillé‐Nion, Catherine Guette, Fabien Gautier, Stéphane Télétchéa, Philippe Paul Juin · 2025 · Nature Communications
12. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling
    Deborah R. Surman, Yuan Xu, Min-Jung Lee, Jane B. Trepel, Kate Brown, Maheshwari Ramineni, Taylor G. Splawn, Laurence P. Diggs, H. Courtney Hodges, Jeremy L. Davis et al. · 2021 · Molecular Cancer Therapeutics
13. Effect of Gaillardin on Proliferation and Apoptosis of Acute Promyelocytic Leukemia Cell Lines, NB4 as Cancer Treatment
    2020 · Biointerface Research in Applied Chemistry
14. Apoptosis-inducing Effect of the Hexane Extracts from Three Native Iranian Euphorbia Plants
    Narjes Shekofteh, Mehri Ghafourian, Neda Khosravi, Kurosh Kalantar, Saeed Malek-Hosseini, Haideh Namdari, Zahra Amirghofran · 2017 · International Journal of Cancer Management
15. Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia
    Patrick Kevin Reville, Tapan Mahendra Kadia · 2020 · Current Treatment Options in Oncology
16. Senolytic Drug Development
    Yonghan He, Guangrong Zheng, Daohong Zhou · 2020 · Healthy ageing and longevity
17. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
    Pavel Klener · 2020 · Expert Opinion on Therapeutic Targets
18. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins
    Jianan Gong, Tirta Mario Djajawi, Donia M. Moujalled, Giovanna Pomilio, Tiffany T. Khong, Liping Zhang, Pasquale Luke Fedele, Michael Sze Yuan Low, Mary Ann Anderson, Christopher D. Riffkin et al. · 2025 · Cell Death and Differentiation
19. Chrysin mitigates therapy-induced senescence in breast cancer via cGAS–STING pathway inhibition
    Rezina Billimoria, Purvi Bhatt · 2025 · Medical Oncology
20. Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer
    Stuthi Pavani Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, Rohit Jain, Changchuan Jiang, Julianne L. Holleran, Robert A. Parise, Robert R. Bies, David I. Quinn, Kristopher M. Attwood et al. · 2025 · Cancer Chemotherapy and Pharmacology
21. The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL
    Maren Christiane Wichert, Colin Fortner, Alexandra Niedermayer, Johanna Bender, Stefanie Enzenmüller, Klaus‐Michael Debatin, Lüder Hinrich Meyer, Felix Seyfried · 2024 · Blood Advances
22. Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
    Satoshi Takagi, Mikako Nakajima, Sumie Koike, Miho Takami, Yoshiya Sugiura, Seiji Sakata, Satoko Baba, Ai Takemoto, Tianyi Huang, Yosuke Seto et al. · 2024 · Oncogene
23. Glucose deprivation promotes apoptotic response to S1 by enhancing autophagy in human cervical cancer cells
    Li Zhou, Qinghuan Kong, Yunhan Zhang, Wei Yang, Shan Yan, Meihui Li, Yidan Wang, Yanjie Zhou, Huimei Yu, Liying Han · 2018 · Cancer Management and Research
24. Multikilogram Synthesis of a Potent Dual Bcl-2/Bcl-xL Antagonist. 2. Manufacture of the 1,3-Diamine Moiety and Improvement of the Final Coupling Reaction
    Christophe Hardouin, Sandrine Baillard, François Barière, Anthony Craquelin, Mathieu Grandjean, Solenn Janvier, Stéphane Le Roux, Christine Penloup, Olivier Russo · 2019 · Organic Process Research & Development
25. Micro-Slab Coil Design for Hyperpolarized Metabolic Flux Analysis in Multiple Samples
    Geonhui Lee, Thomas Ruan, Claudia Wong, Kofi Deh, Alli Abolarin, Alexander Correa, Kayvan R. Keshari, Sangmoo Jeong · 2022 · Bioengineering
26. Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis
    Himanshu N. Bhatt, Rimpy Diwan, Igor L. Estevao, Rui Dong, Jennifer Smith, Chuan Xiao, Sandeep Krishna Agarwal, Md Nurunnabi · 2024 · Journal of Controlled Release
27. The potential for senotherapy as a novel approach to extend life quality in veterinary medicine
    Zoë J. Williams, Lyndah Chow, Steven Dow, Lynn Marie Pezzanite · 2024 · Frontiers in Veterinary Science
28. Rola wenetoklaksu w leczeniu chorych na przewlekłą białaczkę limfocytową
    Bartosz Puła, Krzysztof Jamroziak · 2017 · Hematologia
29. ΔFosB regulates rosiglitazone‐induced milk fat synthesis and cell survival
    Xuefeng Wei, Hui Li, Guangwei Zhao, Jiameng Yang, Lihui Li, Yongzhen Huang, Xianyong Lan, Yun Ma, Linyong Hu, Huiling Zheng et al. · 2017 · Journal of Cellular Physiology
30. Targeting entry into mitochondria for increased anticancer efficacy of BCL-XL-selective inhibitors in lung cancer
    Liangping Li, Pingping Li, Huanhuan Song, Xuesong Ma, Shulan Zeng, Yan Peng, Guohai Zhang · 2022 · Pharmacological Research
31. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia
    Takahiro Kobayashi, Honami Sato, Masatomo Miura, Yayoi Fukushi, Wataru Kuroki, Fumiko Ito, Kazuaki Teshima, Atsushi Watanabe, Naohito Fujishima, Isuzu Kobayashi et al. · 2024 · Cancer Chemotherapy and Pharmacology
32. The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia
    Valentín Ortiz‐Maldonado, Pablo Mozas, Julio Delgado · 2016 · Therapeutic Advances in Hematology
33. Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells
    Natalie Luffman, Fereshteh Ahmadinejad, Ryan Finnegan, Marissa Raymond, David A. Gewirtz, Hisashi Harada · 2025 · International Journal of Molecular Sciences
34. Decoding senescent drivers in Alzheimer's disease: From bench to bedside
    Runjin Zhou, Xiaoling Lin, Zhenge Liao, Jian Lin, Ruixue Zheng, Haojie Ni, Wei Liu, Zhanpeng Feng, Qiuxing He, Xingdong Lin et al. · 2025 · Ageing Research Reviews
35. The PROTAC selectively degrading BCL-XL inhibits the growth of tumors and significantly synergizes with Paclitaxel
    Fenglan Qiu, Yachuan Tao, Yue Chen, Zhuqin Shen, Xuan Huang, Wenfu Tan, Taomin Huang, Xin Cao · 2024 · Biochemical Pharmacology
36. Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids
    Wunan Mi, Gilles S. van Tienderen, Shaojun Shi, Amy Broeders, Kathryn Monfils, Henk P. Roest, Luc J. W. van der Laan, Monique M. A. Verstegen · 2025 · International Journal of Cancer
37. Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax
    Faris Jamal Tayeb · 2024 · Exploration of Medicine
38. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies
    Shuhui Deng, Sanika Derebail, Vera Joy Weiler, Jessica Fong Ng, Elena Maroto-Martín, Madhumouli Chatterjee, Giulia Giorgetti, Chandraditya Chakraborty, Poonam Kalhotra, Ting Du et al. · 2024 · Blood Advances
39. BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis
    Prashanta Kumar Panda, Ana Carolina Paschoalini Mafra, Alliny C.S. Bastos, Li Cao, Maria Serra Bonet, Caitlyn B. Brashears, Ethan Yang Chen, Heather M. Benedict-Hamilton, William R. Ehrhardt, John S. Bomalaski et al. · 2025 · Clinical Cancer Research
40. Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
    Benu Chaudhary, Preeti Arya, Vikas Sharma, Parveen Kumar, Deepak Singla, Ajmer Singh Grewal · 2025 · Bioorganic Chemistry
41. The Role of ΔFosB on the Pro-survival Effect of PTHrP in Goat Mammary Epithelial Cells
    Hui Li, Xiaotong Yao, Lihui Li, Huiling Zheng · 2016 · Applied Biochemistry and Biotechnology
42. Advances in synthetic lethality modalities for glioblastoma multiforme
    Seidu A. Richard · 2024 · Open Medicine
43. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
    Mohamed Ali Badawi, Benjamin Engelhardt, Edyta Dobkowska, Rong Deng, Jonathan L. Kaufman, Rajeev M Menon, Ahmed Hamed Salem · 2024 · Investigational New Drugs
44. A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor
    Kedar S. Vaidya, Anatol Oleksijew, Lora A. Tucker, William N. Pappano, Mark G. Anderson, Christine M. Grinnell, Qian Yun Zhang, Sarah J. Heighton, Michael J. Mitten, Sasmita Mishra et al. · 2017 · Pharmacology
45. Pharmacological modulation of cell death in organ transplantation
    Pietro E. Cippà, Thomas Hans Fehr · 2017 · Transplant International
46. Increased apoptotic priming of glioblastoma enables therapeutic targeting by BH3-mimetics
    Anna L. Koessinger, Dominik Koessinger, Kevin Kinch, Laura Martínez‐Escardó, Nikki R. Paul, Yassmin Elmasry, Gaurav Malviya, Catherine Cloix, Kirsteen J. Campbell, Florian J. Bock et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
47. Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma
    Dan Zhang, Ju Zhu, Rui Zou, Han Zhang, Bao-Ping Yu, Pan Li, Yang Luo, Zheng Jiang, Yu Hou, Jian-Wei Zhang · 2025 · Biochemical Pharmacology
48. Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer
    Anthony Tighe, Louisa Nelson, Robert David Morgan, Bethany M. Barnes, I‐Hsuan Lin, Samantha Littler, James Altringham, Jean Ling Tan, Joanne C. McGrail, Stephen S. Taylor · 2025 · Cell Reports Medicine
49. Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia
    Noomi Vainer, Andreas Katsimigas, Emelie Curovic Rotbain, Carsten Utoft Niemann · 2025 · Hematology/Oncology Clinics of North America
50. Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.
    Irfana Muqbil, Ramzi M. Mohammad · 2015 · Europe PMC (PubMed Central)
51. Embryonic develop-associated gene 1 is overexpressed and acts as a tumor promoter in thyroid carcinoma
    Jinkai Xu, Zongyu Li, Qinghua Su, Jun Zhao, Jiancang Ma · 2016 · Biomedicine & Pharmacotherapy
52. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies
    Jacqueline L. Olin, Carrie L. Griffiths, Morgan B. Smith · 2017 · Journal of Oncology Pharmacy Practice
53. The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo
    Žana Besser Silconi, Vesna Rosic, Sasa Benazic, Gordana D. Radosavljevic, Marina Ž. Mijajlović, Jelena M. Pantic, Zoran Ratković, Gordana P. Radić, Aleksandar Arsenijević, Marija Milovanović et al. · 2022 · International Journal of Molecular Sciences
54. Age-related disease: Skin
    Saranya P. Wyles, Krishna Subhash Vyas, J. Roscoe Wasserburg, Ryeim B. Ansaf, James L. Kirkland · 2024 · Elsevier eBooks
55. Unlocking the Potential of Senolytic Compounds: Advancements, Opportunities, and Challenges in Ageing-Related Research
    Lilian Sales Gomez, Diana Jurk · 2024 · Sub-cellular biochemistry/Subcellular biochemistry
56. Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis
    Akira Kato, Hiroki Takahashi, Hiroyuki Asai, Shuhei Uehara, Shinnosuke Harata, Yoshiaki Fujii, K. Watanabe, Takeshi Yanagita, Takuya Suzuki, Hajime Ushigome et al. · 2024 · Oncology Reports
57. Therapeutics targeting BCL2 family proteins
    Haiming Dai, X. Wei Meng, Kaiqin Ye, Jia Jia, Scott H. Kaufmann · 2021 · Elsevier eBooks
58. The Use of Genetically Modified Animals in Discovery Toxicology
    Dolores Diaz, Jonathan M. Maher · 2016
59. Small Molecule Inhibitors of the Human Histone Lysine Methyltransferase NSD2 / WHSC1 / MMSET Identified from a Quantitative High-Throughput Screen with Nucleosome Substrate
    Nathan P. Coussens, Stephen C. Kales, Mark J. Henderson, Olivia W. Lee, Kurumi Y. Horiuchi, Yuren Wang, Qing Chen, Ekaterina Kuznetsova, Jianghong Wu, Dorian M. Cheff et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
60. Molecular control of the lymphocyte death timer
    Michelle Ruhle, Evan A. Thomas, Edward Dann, Nicole Gottscheber, Charis E. Teh, Daniel H.D. Gray, Mark R. Dowling, Susanne Heinzel, Philip D. Hodgkin · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
61. The role of senescence in cancer therapy-associated cardiovascular toxicity
    Yasmin K. Alshoubaki, Vivienne Grüterich, Valentina Zollet, Gabriela M. Kuster · 2024 · The Journal of Cardiovascular Aging
62. Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma
    Wunan Mi, Antonio Cigliano, Grazia Galleri, Isabella Gigante, Sara Martina Steinmann, Ezgi Cibali, Marina Serra, Giovanni Mario Pes, Denise Schlösser, Elena Pizzuto et al. · 2025 · JHEP Reports
63. Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma
    Qinghua Zeng, Yan Zhang, Yiwen Yang, Xin Liu, Xin Dong, Yongzhang Pan, Li Hu, Ao Zhang, Jian Yang, Qiuni Luo et al. · 2026 · BMC Medicine
64. Profiling of BCLxL Protein Complexes in Non-Small Cell Lung Cancer Cells via Multiplexed Single-Molecule Pull-Down and Co-Immunoprecipitation
    Shi Ho Kim, Changju Chun, Tae‐Young Yoon · 2024 · Analytical Chemistry
65. Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3 ‐mimetics using virtual tumors calibrated with cell viability assays
    Thibaud Derippe, Sylvain Fouliard, Xavier Declèves, Donald E. Mager · 2024 · CPT Pharmacometrics & Systems Pharmacology
66. Pitfalls of Combining Novel Agents in Lymphoma
    Thomas David Rodgers, Paul M. Barr · 2018 · Current Treatment Options in Oncology
67. A dual-functional nanomedicine combining fluorinated antisense oligonucleotide with chemotherapeutic drug for synergistic gene-chemo tumor treatment
    Yuhong Lin, Zhangcheng Fu, Yongfei Liu, Jingyi Chen, Kai Zhao, Chunhua Lü, Xian-kun Tu · 2023 · Materials & Design
68. A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-X L Anti-apoptotic Protein in Kidney Cancer
    Treg M. Grubb, Smruthi Maganti, John Michael Krill-Burger, Cameron S. Fraser, Laura A. Stransky, Tomas Radivoyevitch, Kristopher A. Sarosiek, Francisca Vázquez, William G. Kaelin, Abhishek A. Chakraborty · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
69. GosB Inhibits Triacylglycerol Synthesis and Promotes Cell Survival in Mouse Mammary Epithelial Cells
    Gaoxiao Xu, Saixing Duan, Jianye Hou, Wei Zhongxin, Guangwei Zhao · 2017 · BioMed Research International · Retracted
70. Development of molecular intervention strategies for B-cell lymphoma
    Wenyujing Zhou, Weihong Chen · 2020 · Expert Review of Hematology
71. Current Status of Molecularly Targeted Therapeutics in Blood Cancers
    Caitlin Kumala, Lynh Vu, Tamer E. Fandy · 2025 · International Journal of Molecular Sciences
72. Molecular interactions of cinnamyl and quinoxaline derivatives with Bcl-2 antiapoptotic proteins: a computational study
    Imelda Lizeth Lazcano Carrasco, Carlos Zepactonal Gómez-Castro, Luis Ángel Zárate-Hernández, Rosa Luz Camacho-Mendoza, Simplicio González Montiel, Marco Franco‐Pérez, Julián Cruz‐Borbolla · 2026 · Organic & Biomolecular Chemistry
73. Pyrazoline–Imidazopyridine Hybrids as Beclin‐1 Mimetics Driving Dual Apoptotic and Autophagy in Breast Cancer
    Rashmi Shivakumar, Narasimha Murthy Beeraka, Riyaz Ali M. Osmani, Bhoomika B. Ravi, Monisha H. S. Yadhav, Dileep Nagaraju, Chandra Sekhar Bhol, Allaka Nagalakshmi, Kwang Seok Ahn, Vladimir N. Nikolenko et al. · 2026 · Chemical Biology & Drug Design
74. BCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers
    Tupa Basuroy, Treg M. Grubb, Ananthan Sadagopan, Xingping Qin, Kylee Madison, Autumn Hall, Belinda B. Willard, Sakari Vanharanta, Kristopher A. Sarosiek, Srinivas R. Viswanathan et al. · 2026 · Cell Death and Disease
75. Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy
    Konstantinos V. Floros, Anthony C. Faber, Hisashi Harada · 2018 · Resistance to targeted anti-cancer therapeutics
76. Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis
    Yasuhiro Nakano, Yoshikazu Johmura · 2023 · Annals of Hepatology
77. B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
    Rui Caetano Oliveira, João Martins Gama, José Casanova · 2023 · Exploration of Targeted Anti-tumor Therapy
78. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma
    Clare M. Adams, Amanda McBride, Peter Michener, Irina S. Shkundina, Ramkrishna Mitra, Hyun Hwan An, Pierluigi Porcu, Christine M. Eischen · 2024 · Cancers
79. Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family
    Ali Farhang Boroujeni, Zeynep Ateş‐Alagöz · 2024 · Anti-Cancer Agents in Medicinal Chemistry
80. BAX requires VDAC2 to mediate apoptosis and to limit tumor development
    Hui San Chin, Mark F. van Delft, Robert L. Ninnis, Xiang Li, Iris K. L. Tan, Boris Reljić, Kristen Scicluna, Laura F. Dagley, Jarrod John Sandow, Gemma L. Kelly et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
81. ER shaping proteins regulate mitochondrial fission, outer membrane permeabilization and apoptosis
    Mateus Milani, Gerald M. Cohen, Shankar Varadarajan · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
82. IAP antagonists potentiate TNFα-triggered apoptosis but selectively eliminate senescent tumor cells independently of TNFα
    Hiroaki Ochiiwa, Takeshi Wakasa, Yuki Kataoka, Koji Ando, Eiji Oki, Yoshihiko Maehara, Makoto Iimori, Hiroyuki Kitao · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
83. Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors
    Kirsi Toivanen, Astrid Murumägi, Agnieszka Woźniak, Karo Wyns, Chao‐Chi Wang, Luna De Sutter, Mariliina Arjama, Nanna Merikoski, Sami Salmikangas, Omar Youssef et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
84. EFFECTIVENESS OF VENETOСLAX IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (LITERATURE REVIEW)
    Vladimir Vladimirovich Strugov, Elena Stadnik, Andrey Yu. Zaritskey · 2017 · Oncohematology
85. Is venetoclax a new wonder drug in CLL ?
    Chris Fegan, Chris J. Pepper · 2019 · British Journal of Haematology
86. Combinatorial Genetic Screening in Cancer
    Fadi J. Najm · 2019 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
87. BCL-XL is essential for the protection from secondary anemia caused by radiation-induced fatal kidney damage
    Kerstin Brinkmann, Paul Waring, Stefan P. Glaser, Verena C. Wimmer, Duong Nhu, Lachlan W. Whitehead, Alex R. D. Delbridge, Guillaume Lessène, Marco J. Herold, Gemma L. Kelly et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
88. Mechanisms of BAK Activation in the Initiation of Mitochondrial Apoptosis
    Geetika Singh · 2020
89. Selective BCL-X L Antagonists Eliminate Infected Cells from a Primary Cell Model of HIV Latency but not from Ex Vivo Reservoirs
    Yanqin Ren, Szu-Han Huang, Amanda B. Macedo, Adam R. Ward, Winiffer D. Conce Alberto, Thaís Klevorn, Louise Leyre, Dora Chan, Ronald Truong, Thomas M. Rohwetter et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
90. Apatinib Sensitizes Human Breast Cancer Cells against Navitoclax and Venetoclax Despite Up-regulated Bcl-2 and Mcl-1 Gene Expressions
    Berna Kavakcıoğlu Yardımcı · 2021 · Turkish Journal of Oncology
91. El régimen de sucesiones
    Fernando García Vicente · 2002 · Anales: Anuario del centro de la UNED de Calatayud
92. A matter of life or death: targeting MCL-1 in multiple myeloma
    Anne Slomp · 2021 · Utrecht University Repository (Utrecht University)
93. Forligsmæssig afskedigelse. Afgørelsesbegrebet i forvaltningsloven
    jasv · 1998
94. 频道制全成本核算：预算是核心，节目质量是根本
    刘晓岗 · 2010 · 视听界
95. PARSING THE CONTRIBUTIONS OF THE BCL-2 ANTI-APOPTOTIC PROTEINS IN MEDIATING SURVIVAL OF NASOPHARYNGEAL CARCINOMA CELL LINE HK1 USING BCL-2 SELECTIVE INHIBITORS
    Siti Fairus Abdul Rahman, Nethia Mohana‐Kumaran · 2020 · Malaysian Applied Biology
96. A Functional Pre-Screening Platform for Identifying Points of Vulnerability in the Cell Death Map of Human Melanoma Tumors
    Naama P. Dekel‐Bird, Shani Bialik, Orit Itzhaki, Tomer Meir Salame, Naama Yaeli-Slonim, Vered Levin‐Salomon, Santosh K. Dasari, Michal Judith Besser, Adi Kimchi · 2022 · Journal of Cancer Science and Clinical Therapeutics
97. Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
    Larissa Ewald · 2021
98. Faculty Opinions recommendation of Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Varsha V. Gandhi, Prithviraj Bose · 2017 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
99. Faculty Opinions recommendation of A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
    Ye Che · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
100. Faculty Opinions recommendation of BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells.
     Andrew P. Gilmore · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature